This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...
The US Food and Drug Administration (FDA) has granted the lead asset for FELIQS, FLQ-101, Fast Track designation for the prevention of retinopathy of prematurity (ROP). According to a press release 1 ...
David Arkowitz, MBA, has joined Alkeus Pharmaceuticals as Chief Financial Officer. Prior to joining Alkeus, Arkowitz served as Executive Vice President, Chief Financial Officer and Head of Business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback